| Title: | Distribution of human papilloma virus genotypes and treatment outcomes in definitive radiotherapy for cervical cancer |
| Authors: | Kinoshita, Rumiko Browse this author →KAKEN DB |
| Mitamura, Takashi Browse this author →KAKEN DB |
| Kato, Fumi Browse this author |
| Hattori, Takahiro Browse this author |
| Higaki, Hajime Browse this author |
| Takahashi, Shuhei Browse this author |
| Fujita, Yoshihiro Browse this author |
| Otsuka, Manami Browse this author |
| Koizumi, Fuki Browse this author |
| Uchinami, Yusuke Browse this author |
| Mori, Takashi Browse this author |
| Nishioka, Kentaro Browse this author |
| Hashimoto, Takayuki Browse this author |
| Ito, Yoichi M. Browse this author |
| Watari, Hidemichi Browse this author |
| Aoyama, Hidefumi Browse this author →KAKEN DB |
| Keywords: | cervical cancer |
| definitive radiotherapy |
| human papilloma virus (HPV) genotype |
| prognosis |
| Issue Date: | Mar-2023 |
| Publisher: | Oxford University Press |
| Journal Title: | Journal of Radiation Research |
| Volume: | 64 |
| Issue: | 2 |
| Start Page: | 463 |
| End Page: | 470 |
| Publisher DOI: | 10.1093/jrr/rrac086 |
| Abstract: | Most oncogenic human papilloma virus (HPV) genotypes stratify into two species, alpha-7 HPV and alpha-9 HPV. There are several studies that evaluate the relationship between HPV species and treatment outcomes and reports that HPV species is prognostic. The HPV genotyping was conducted using biopsy specimens which had been stored in these studies. We conducted the study using the HPV test performed by cytology specimens which is less invasive and more useful in clinical settings. This study enrolled 46 patients who received HPV genotyping before the definitive radiotherapy. The results of the HPV genotyping were classified into HPV alpha-7, HPV alpha-9 and negatives. Of the 46 patients, 10 were positive for HPV alpha-7, 21 positive for HPV alpha-9 and 15 were negative. The median follow-up period was 38 months (range 4-142). The HPV alpha-7, HPV alpha-9 and negative groups showed the 3-year overall survival (OS; 59.3%, 80.4% and 72.2% [P = 0.25]); local control (LC; 67.5%, 81% and 80% [P = 0.78]); pelvic control (PC) (50%, 81% and 72.7% [P = 0.032]); pelvic lymph node (PLN) control (78.7%, 95% and 92.3% [P = 0.012]); distant metastasis free (DMF) survival (50%, 75.4% and 42.8% [P = 0.098]); and progression free survival (PFS) rate of patients (30%, 66.7% and 38.9% [P = 0.085]), respectively. Patients with HPV alpha-7 showed statistically significant poorer PC than the HPV alpha-9 group, in multivariate analysis. This result is consistent with previous studies for HPV positive patients. The HPV negativity rate was higher in this study than in other studies and further work on this may be needed for clinical use. |
| Type: | article |
| URI: | http://hdl.handle.net/2115/88794 |
| Appears in Collections: | 北海道大学病院 (Hokkaido University Hospital) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)
|
